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Two related classical swine fever virus (CSFV) strain Brescia clones were isolated from blood samples from
an infected pig. Virus C1.1.1 is a cell-adapted avirulent variant, whereas CoBrB is a virulent variant. Sequence
analysis revealed 29 nucleic acid mutations in C1.1.1, resulting in 9 amino acid substitutions compared to the
sequence of CoBrB 476R. Using reverse genetics, parts of the genomes of these viruses, which contain differ-
ences that lead to amino acid changes, were exchanged. Animal experiments with chimeric viruses derived from
C1.1.1 and CoBrB 476R showed that a combination of amino acid changes in the structural and nonstructural
regions reduced the virulence of CSFV in pigs. Moreover, the presence of a Leu at position 710 in structural
envelope protein E2 seemed to be an important factor in the virulence of the virus. Changing the Leu at
position 710 in the CoBrB 476S variant into a His residue did not affect virulence. However, the 710His in the
C1.1.1/CoBrB virus, together with adaptive mutations 276R, 476R, and 477I in Erns, resulted in reduced virulence
in pigs. These results indicated that mutations in Erns and E2 alone do not determine virulence in pigs. The
results of in vitro experiments suggested that a high affinity for heparan sulfate of C1.1.1 Erns may reduce the
spread of the C1.1.1/CoBrB virus in pigs and together with the altered surface structure of E2 caused by the
710L3H mutation may result in a less efficient infection of specific target cells in pigs. Both these features
contributed to the attenuation of the C1.1.1/CoBrB virus in vivo.
Classical swine fever is a highly contagious and sometimes
fatal viral disease in pigs. The causative agent, classical swine
fever virus (CSFV), is a member of the Pestivirus genus within
the family Flaviviridae (37). The other two members of this
genus are bovine viral diarrhea virus (BVDV) and border
disease virus. CSFV has been found to be infectious only for
pigs. BVDV and border disease virus can infect both rumi-
nants and pigs (3). Pestiviruses are small, enveloped, plus-
strand RNA viruses (22). The RNA genome is approximately
12.5 kb (1, 4, 19, 25) and contains a single large open reading
frame (ORF) (1, 5, 19, 25), which is flanked by 5 and 3
nontranslated regions (NTRs). This ORF is translated into a
polyprotein, which is further processed into mature proteins by
viral and host cell proteases (27).
The surface structure of pestivirus virions is composed of
three glycoproteins, Erns, E1, and E2 (30). E2 is present as a
homodimer and as an E2-E1 heterodimer (30, 39). The C
terminus of E2 (and probably of E1 as well) functions as a
membrane-spanning domain (13) and anchors the E2-E1 and
E2-E2 dimers in the viral lipid membrane. The association of
Erns homodimers with the virion is not accomplished by a
membrane-spanning domain and is tenuous (7). The mecha-
nism of Erns association with virions is currently unknown. All
three envelope proteins contain N-linked glycosyl groups (27,
30, 39). Erns is glycosylated to a higher extent than E1 and E2
are. N-linked glycosyl residues account for about half of the
mass of an Erns homodimer (27, 44). A considerable portion of
the Erns protein produced in infected cells is secreted into the
extracellular environment and circulates in the body fluids of
infected animals (27). The unexpected finding that Erns pos-
sesses RNase activity (9, 28) led to several interesting studies
regarding the function of Erns in the life cycle of pestiviruses.
The results of in vitro and in vivo studies indicated that Erns
(and its enzyme activity) plays a role in the regulation of RNA
synthesis in infected cells (10) and in weakening the immune
defense of the host early in infection (2, 20).
Recently, it was demonstrated that in vitro cultivation of
CSFV in swine kidney cells selects virus variants that attach to
the surfaces of cultured cells by interaction with the mem-
brane-associated glycosaminoglycan heparan sulfate (HS)
(11). Using reverse genetics, it was shown that replacement of
a neutral serine residue by a positively charged arginine resi-
due in the C terminus of Erns (position 476 in the ORF)
changes an HS-independent CSFV to a virus that uses HS as
an Erns receptor. These findings showed that interaction of
virus-bound Erns with HS immobilizes CSFV on the surfaces of
cultured swine kidney cells. Animal experiments showed that
this Ser-to-Arg change in the C terminus of Erns did not affect
virulence (12). In the same study, it was shown that virus
reisolated from pigs infected with the HS-independent recom-
binant virus was able to infect cultured and primary swine
kidney cells by an HS-dependent mechanism. These results
suggested that the surface properties of CSFV generated in
pigs and carrying 476Ser in the C terminus of Erns are distinct
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from those of genetically identical virus produced in cell cul-
ture.
Field isolates and laboratory strains of CSFV vary consider-
ably in their virulence, but until now, no genetic determinants
of virulence could be defined despite extensive efforts in se-
quencing and detailed phylogenetic studies (14, 35). The same
holds true for the search for in vitro parameters that would
allow grouping of viruses into virulence classes. No significant
qualitative or quantitative differences were found between
CSFV strains with different degrees of virulence when RNA
replication and protein synthesis were investigated by Mittel-
holzer et al. (21). However, these researchers showed that
reduced particle release from SK6 cells was inversely corre-
lated with the virulence of CSFV strains.
Altered virulence properties of viral variants are the basis
for their application as live attenuated vaccines. Therefore, it is
of particular interest to elucidate the mechanisms causing virus
variants to lose the capacity to produce disease in a host and
link them to genetic changes in their genomes. Potential mech-
anisms for the attenuation of viral virulence include the fol-
lowing: (i) changes in viral binding and penetration properties
on host membranes, resulting in altered tissue tropisms; (ii) a
reduction of viral replication rate in vivo; (iii) a decreased
efficiency of virus spread in the host; and (iv) an increased
susceptibility of variant viruses to host antiviral responses (re-
viewed in reference 31). Virulence attenuation has tradition-
ally been achieved by serial passage of virus in cultured cells or
laboratory animals (or both), a selection process that can give
rise to adaptive changes that result in reduced virulence in the
natural or incidental hosts.
We report here on the mechanism for virulence attenuation
of laboratory-derived CSFV variants with altered attachment
and surface properties in vitro. Therefore, sequences of a vir-
ulent Brescia variant (CoBrB 476R [11]) and a cell-adapted
avirulent variant C1.1.1 (41), isolated from blood samples from
a pig infected with CSFV strain Brescia, were compared. We
studied the roles of these adaptive amino acid changes by
generating chimeric CSFVs from full-length cDNA constructs.
Infection of pigs with these recombinant viruses revealed a
possible role of the adaptive Leu3His mutation at position
710 of the polyprotein, but the 710His variant resulted in an
avirulent virus only when the variant also contained three
adaptive mutations in Erns. Analysis of in vitro- and in vivo-
generated viruses suggested that both the high affinity for HS
and an altered surface structure of E2 may result in a less
efficient infection of specific target cells in pigs. Both these
features contribute to the attenuation of CSFV strain Brescia
in vivo.
MATERIALS AND METHODS
Cells and viruses. The swine kidney cell line SK6 (15) was maintained as
described previously (32). Porcine lung macrophages were isolated from the
lungs of 6-week-old specific-pathogen-free piglets as described previously (42).
Fetal bovine serum (FBS) and cells were free of BVDV, and the FBS was free
of anti-BVDV antibodies. CSFV strain Brescia was isolated from a pig infected
with a virulent field isolate (isolate 456610) (40). Brescia virus was grown for 24
passages on PK15 cells and cloned by repeating endpoint dilution (three times).
This virus clone (C1.1.1) was passaged three times on PK15 cells to produce a
virus stock. This virus stock was adapted to growth on SK6 cells by two extra
passages (11). The recently constructed recombinant virus vflC1.1.1 ErnsR-RI
(11) was derived from the SK6-produced virus stock. Isolation of the HS-inde-
pendent Brescia virus clone Bp2 and its HS-dependent counterpart, Bp3, which
was passaged one more time in SK6 cells, have been described recently (11). The
constructed recombinant viruses derived from Brescia were named vflCoBrB
ErnsS-ST (clone Bp2) and vflCoBrB ErnsS-RT (clone Bp3) and have been char-
acterized as being as virulent as the pig isolate 456610 that they were isolated
from (11). In this article, viruses vflC1.1.1 ErnsR-RI, vflCoBrB ErnsS-ST, and
vflCoBrB ErnsS-RT will be referred to hereafter as C1.1.1, CoBrB 476R, and
CoBrB 476S, respectively.
Sequence comparison of recombinant viruses C1.1.1 and CoBrB 476R. The
isolation and sequencing of virus clones C1.1.1 and CoBrB 476R have been de-
scribed elsewhere (11, 24). The genomic sequences were compared using Auto-
Assembler software (Applied Biosystems). Sequence mutations between the two
Brescia clones were confirmed by sequencing independent PCR fragments.
Construction, generation, and characterization of chimeric viruses derived
from C1.1.1, CoBrB 476R, and CoBrB 476S. Recently, full-length DNA copies of
clones C1.1.1 and CoBrB of CSFV Brescia strain have been described (11, 12).
These DNA copies were constructed in the same manner as the full-length
cDNA of CSFV strain C in low-copy-number plasmid pOK12 (23). The junction
between the T7 RNA polymerase promoter sequence and the 5-terminal nu-
cleotide of C1.1.1 and CoBrB and the junction between the 3-terminal nucleo-
tide of C1.1.1 and CoBrB and the vector were similar to those described for the
full-length copy of strain C in pOK12 (23). Digestion of these full-length cDNAs
in pOK12 (named pflC1.1.1 or pflCoBrB) with SrfI generates the exact 3 ter-
minus of the RNA genome of pflC1.1.1 and pflCoBrB. The viruses derived from
these two full-length clones are named C1.1.1 and CoBrB 476R, respectively.
Animal experiments showed that C1.1.1 is avirulent (11) and CoBrB 476R is
virulent (12). The first chimeric constructs were derived from pflC1.1.1 and
pflCoBrB 476R, focusing on the amino acid mutations between pflC1.1.1 and
pflCoBrB 476R.
To introduce the three adaptive mutations located in the structural region
from pflC1.1.1 into a virulent background (pflCoBrB 476R), the ClaI/NcoI frag-
ment (nucleotides [nt] 778 to 5534) from pflC1.1.1 was introduced into ClaI/
NcoI-digested pflCoBrB 476R. This resulted in a full-length cDNA pflC1.1.1/
CoBrB with adaptive mutations 276S3R and 477T3I in Erns and 710L3H in E2
(see Fig. 3). To introduce the remaining six adaptive amino acid mutations
located in the nonstructural region from pflC1.1.1 into a virulent background
(pflCoBrB 476R), the NcoI/AatII fragment (nt 5534 to 12279) from pflC1.1.1 was
introduced into NcoI/AatII-digested pflCoBrB 476R. This resulted in a full-
length cDNA pflCoBrB 476R/C1.1.1 with adaptive mutations 1915A3S and
1971S3P in NS3, 2638L3V in NS4b, 2846R3C in NS5a, and 3419N3I and
3858V3A in NS5b (see Fig. 3). A third full-length cDNA, in which CoBrB 476R
was introduced into pflC1.1.1, was constructed by introducing the ClaI/NgoMIV
fragment (nt 778 to 2439) of pflCoBrB 476R into ClaI/NgoMIV-digested
pflC1.1.1. This construct was named pflC1.1.1/CoBrB (Npro-C-Erns-E1) (ex-
changed proteins shown in parentheses; hybrid proteins resulting from the fusion
of C1.1.1 and CoBrB indicated by a prime after the protein) (see Fig. 3).
The second series of chimeric full-length cDNAs were based on pflC1.1.1 and
pflCoBrB 476S, focusing on the role of the 710H3L in E2. Therefore, the
NgoMIV/NcoI fragment (nt 2439 to 5534) of pflC1.1.1 was introduced into
pflCoBrB 476S, resulting in a full-length copy of pflCoBrB 476S/C1.1.1 (E2-p7-
pNS2-3) (see Fig. 3). For the construction of pflCoBrB/C1.1.1 (Npro-C-Erns-
E1), the NgoMIV/NcoI fragment (nt 2439 to 5534) of pflCoBrB 476S was intro-
duced into pflC1.1.1/CoBrB.
SrfI-linearized DNA (250 ng) of full-length plasmids was transfected into
SK6.T7a5 cells as described previously (33). Two days after transfection, the
medium was harvested and stored at 70°C, and cells were immunostained with
monoclonal antibody (MAb) V3 directed against E2 (38). A portion (100 l) of
the medium collected from wells in which E2 expression was detected (virus
passage number 1 [p1]) was used to infect confluent monolayers of SK6 cells
grown in 2-cm2 tissue culture wells. After 2 days of growth, cells were treated
with trypsin, 90% of the cells were transferred to a 25-cm2 tissue culture flask,
and 10% of the cells were transferred to a 2-cm2 tissue culture well. After 3 days
of growth, wells were immunostained with MAb V3 and flasks were freeze-
thawed twice to prepare virus stock p2. The percent inhibition or reduction of
infection of SK6 cells with these recombinant viruses by 225 g of heparin per ml
was determined as described below.
Virus isolation from clinical samples. Leukocytes (white blood cells) were
isolated from blood treated with EDTA as described recently (6). Isolated
leukocytes were resuspended in the same volume of medium (Eagle basal me-
dium containing 10% FBS and antibiotics) as the volume of blood that was used
for isolation. Leukocyte suspensions were stored at 70°C. Tissue suspensions
(10% [wt/vol]) in Eagle minimal essential medium with Earle salts (EMEM)
containing 5% FBS and antibiotics were prepared as described previously (6).
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These suspensions were stored at 70°C. EDTA-treated blood was frozen at
70°C without further treatment. All leukocyte, tissue, and blood samples,
frozen once at 70°C were thawed, divided in aliquots, and stored again at
70°C. In all tests, virus samples that had been freeze-thawed twice were used.
Chemicals, enzymes, and recombinant proteins. Heparin (195 U/mg from
porcine intestinal mucosa) and concanavalin A (ConA) were obtained from
Sigma, St. Louis, Mo. Lyophilized enzyme was dissolved in storage buffer and
stored in aliquots at70°C as described previously (11). Heparin and ConA were
dissolved in EMEM lacking both FBS and antibiotics and stored at 4°C for no
longer than 2 weeks.
Inhibition experiments. In the plaque assay, confluent monolayers of SK6
cells, grown in 2-cm2 tissue culture wells, were washed twice with EMEM lacking
both FBS and antibiotics. The cells were preincubated at 37°C for 30 min with
150 l of EMEM with 300 g of heparin per ml. Fifty microliters of a dilution of
a virus stock in EMEM was added to the wells, mixed, and incubated as described
above. The concentration used in the text and figures hereafter corresponds with
this diluted concentration (225 g of heparin per ml). After 30 min, the virus was
removed, and the wells were washed twice with 0.5 ml of EMEM and supplied
with overlay medium (containing methylcellulose). Cells were grown for 18 h at
37°C, and infectious centers (hereafter referred to as plaques) were detected by
immune staining with E2-specific MAb V3. Positive plaques in a well were
counted with a microscope. When more than 250 plaques per well were present,
a minimum of 100 plaques in a fixed area (at a magnification of 40) were
counted to calculate the total number of plaques in these wells. Percent inhibi-
tion was calculated using the formula 100  [1  (e/c)], where c is the average
number of plaques in duplicate or triplicate wells to which no heparin was added
(control well) and e is the average number of plaques in duplicate or triplicate
wells to which heparin was added. Percent infection compared to control wells
was calculated using the formula 100  (e/c). For all virus samples, the percent-
age of inhibition was determined at two different multiplicities of infection
(MOIs). For all samples, no seriously different percentages were measured when
different amounts of viruses were tested for inhibition by heparin. Therefore,
percentages measured at the highest MOI are presented. Relative plaque sizes of
viruses were scored in wells to which no heparin was added after 48 h of growth
under overlay medium.
Macrophage plaque assay. Infection of alveolar macrophages with CSFV was
measured using a modified plaque assay as described by Hulst et al. (12), except
no heparin or heparinase I was used in our assay.
ConA inhibition or stimulation assay. Viruses were tested for inhibition or
stimulation of infection with different concentrations of ConA as described
previously (12).
Ratio of secreted virus to cell-associated virus. SK6 cells grown in 24-well
plates were infected with viruses at an MOI of 1. After infection for 30 min, cells
were washed two times with complete medium before 1 ml of complete medium
was added to each well. At 2 days postinfection (p.i.), the supernatant was
collected and stored at 70°C. One milliliter of complete medium was added to
the cells in each well before they were freeze-thawed twice at 70°C. Samples
were titrated on SK6 cells in 24-well plates in a plaque assay. The ratio of
secreted virus to cell-associated virus was determined in a plaque assay and
calculated by the following formula: ratio  log10 PFU of cell-associated virus 
log10 PFU of secreted virus.
Virus neutralization index. The titers of in vitro- or in vivo-generated viruses
CoBrB 476S, CoBrB 476S/C1.1.1 (E2-p7-pNS2-3), CoBrB/C1.1.1 (Npro-C-Erns-
E1), and C1.1.1/CoBrB in the presence or absence of neutralizing antibodies
were determined. The virus neutralization index is the log reduction of virus titer,
measured in 50% tissue culture infective doses (TCID50s), by neutralizing MAb
or polyclonal antibodies (PAbs). The virus neutralization index was determined
for MAb V4 and V6 and a serum sample (PabR-RI H) from blood taken at day
21 p.i. from a C1.1.1/CoBrB-infected pig (animal 5021 [see Table 2]). MAb V4
(4 mg/ml) is directed against a conserved epitope in domain A of the E2 protein
of CSFV (38) and was used at a dilution of 1:50. MAb V6 (4 mg/ml) is directed
against a nonconserved epitope in domain B of CSFV E2 and was previously
characterized as a MAb-resistant mutation for MAb V6 (34) and was diluted at
a dilution of 1:50. PabR-RI H serum was used at a dilution of 1:1,000.
Animal experiments. CSFV recombinant virus stocks (p2) of C1.1.1, CoBrB
476R, C1.1.1/CoBrB (Npro-C-Erns-E1), C1.1.1/CoBrB, and CoBrB 476R/C1.1.1
for animal experiment 1 and virus stocks of CoBrB 476S, CoBrB 476S/C1.1.1
(E2-p7-pNS2-3), CoBrB/C1.1.1 (Npro-C-Erns-E1), and C1.1.1/CoBrB for ani-
mal experiment 2 were diluted in SK6 tissue culture medium to a concentration
of 105 TCID50 per ml (as determined by titration on SK6 cells). Groups of three,
6-week-old, specific-pathogen-free pigs were infected by spraying 1 ml of this
virus dilution in each nostril on day 0. In animal experiment 2, one sentinel was
placed 24 h p.i. in the stable of each group of three infected pigs, allowing contact
exposure with the other pigs. All animals were observed daily for signs of disease,
and body temperatures were measured. Fever is defined here as a body temper-
ature of 40°C for at least 2 consecutive days. EDTA-treated blood samples
were taken on days 0, 2, 4, 7, 9, 11, 14, 16, 18, 21, and 23. These blood samples
were used for isolation of virus from leukocytes (see below) and for monitoring
the concentration of thrombocytes and leukocytes. Thrombocytes and leukocytes
were counted as described previously (6). Serum samples were taken on days
0, 7, 14, 21, and 23 and tested in an enzyme-linked immunosorbent assay
(ELISA) that specifically detects antibodies directed against envelope protein
E2 (Ceditest-Ab kit). Pigs were killed when moribund or slaughtered at the end
of the trial. At the postmortem examination, tissue samples of the spleen, kidney,
tonsil, and ileum were collected, frozen in liquid nitrogen, and stored at 70°C.
Duplicate cryostat sections of these tissue samples were tested for viral antigen
using a direct immunofluorescence technique (6).
RESULTS
Sequence comparison of viruses C1.1.1 and CoBrB 476R. To
find genetic factors that determine the virulence of CSFV
Brescia, we cloned and sequenced CoBrB 476R cDNA and
compared this sequence to the cDNA sequence of C1.1.1. We
found 29 nucleic acid mutations, which resulted in 9 amino
acid substitutions (Fig. 1). No sequence differences were found
in the 5 and 3 NTRs of Brescia C1.1.1 and CoBrB 476R
strains, suggesting that these regions of the genome do not
determine the virulence of the two viruses. The amino acid
FIG. 1. Comparison of the cDNA sequences of C1.1.1 and CoBrB 476R. Only 29 nucleic acid differences were found (shown above the genome
bar); these differences resulted in 9 amino acid substitutions (shown below the genome bar). The sequence differences are shown in the following
order: CoBrB 476R  C1.1.1 (original sequence to the adaptive sequence).
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sequences of C1.1.1 (25) and CoBrB 476R were compared with
those of CSFV strains Alfort (26), ALD (14), GPE (14), and
C (23). Except for the amino acid at position 2846 in nonstruc-
tural protein NS5A, the amino acids of virulent CoBrB 476R
and other virulent and avirulent CSFV strains are conserved
compared to those of the C1.1.1 sequence (Fig. 2).
Construction and characterization of chimeric viruses de-
rived from C1.1.1 and CoBrB 476R. To study the role of adap-
tive amino acid mutations on virulence, three chimeric cDNAs
were constructed by exchanging parts of the genomes of C1.1.1
and CoBrB 476R. The first full-length cDNA (pflC1.1.1/CoBrB)
contains the three adaptive amino acid mutations in the struc-
tural region of C1.1.1, 276R and 477I in Erns and 710H in E2 (Fig.
3) in a virulent background of CoBrB 476R. The second full-
length cDNA (pflCoBrB 476R/C1.1.1) contained the six adap-
tive amino acid mutations in the nonstructural region originat-
ing from C1.1.1, 1915S and 1971P in NS3, 2638V in NS4b, 2846C
in NS5a, and 3419I and 3858A in NS5b (Fig. 3). The last of these
full-length cDNAs [pflC1.1.1/CoBrB (Npro-C-Erns-E1)] con-
tains the six adaptive amino acid mutations in the nonstruc-
tural region originating from C1.1.1, 1915S and 1971P in NS3,
2638V in NS4b, 2846C in NS5a, and 3419I and 3858A in NS5b, and
the adaptive amino acid mutation 710H in E2 (Fig. 3).
Transfection of SrfI-linearized full-length DNAs into SK6.T7
cells (33) yielded the infectious recombinant viruses C1.1.1/
CoBrB, CoBrB 476R/C1.1.1, and C1.1.1/CoBrB (Npro-C-Erns-
E1). The transfection medium was used to infect SK6 cells in
order to produce p2 virus stocks. The introduced mutations
were confirmed by sequencing the amplified DNA of these
virus stocks. Virus titers of the p2 stocks of the recombinant
viruses were comparable [7.5  107 TCID50/ml for C1.1.1/
CoBrB, 8  107 TCID50/ml for CoBrB
476R/C1.1.1, and 7.3 
107 TCID50/ml for C1.1.1/CoBrB (N
pro-C-Erns-E1)] to those
of the parent viruses C1.1.1 (7.3  107 TCID50/ml) and CoBrB
ErnsS-RT (7.05  107 TCID50/ml). No growth differences on
porcine alveolar macrophages or SK6 cells could be detected
(results not shown).
Virulence of chimeric viruses derived from C1.1.1 and
CoBrB 476R. To analyze the effects of the adaptive amino acid
mutations on virulence in pigs, animal experiments were con-
ducted. Pigs were infected intranasally according to the regi-
men described in Materials and Methods, and results are
shown in Table 1.
Pigs infected with the full-length clone of cell-adapted avir-
ulent Brescia clone C1.1.1 (group A) showed no signs of CSF
(Table 1). All animals developed a mild leukopenia between
days 2 and 7. Analysis of serum samples showed that all ani-
mals developed antibodies against E2 in serum samples. No
viral antigen could be detected in tonsil, spleen, kidney, and
ileum tissue samples after slaughter. Only one pig (pig 4052)
developed a mild fever for a short period (3 days) and showed
thrombocytopenia. Virus was isolated from blood from this pig
at day 7.
In contrast, pigs infected with the virulent CoBrB 476R strain
(group B) rapidly developed fever (40°C) for a period of
more than 10 days and symptoms of acute CSF (Table 1). All
pigs became seriously ill, as indicated by the lack of appetite,
vomiting, dullness, blue ears, and paresis. All animals devel-
oped leukopenia and thrombocytopenia. Pig 4062 (group B)
developed the chronic form of CSF. No antibodies against E2
were detected in serum samples of this pig, and the pig re-
mained viremic until the end of the trial. After slaughter, viral
antigen could also be detected in tissue samples of all pigs.
These results clearly showed the avirulent phenotype of C1.1.1
and the virulent phenotype of CoBrB 476R.
Only virus CoBrB 476R/C1.1.1 (group C) exhibited a level of
virulence (death, fever, and clinical signs) comparable to that
of CoBrB 476R (group B) (Table 1). One pig in group C (pig
4058), however, recovered after having only mild signs of CSF.
The presence of antibodies against E2 in serum samples of this
pig confirmed infection with CSFV. Virus C1.1.1/CoBrB
(group D) caused a mild form of CSF (Table 1). This virus
caused fever for several days, and typical signs of CSF were
observed in pigs. The pigs of group D recovered rapidly, except
FIG. 2. Multiple-sequence alignment of the amino acid sequences of C1.1.1 and CoBrB 476R with the sequences of virulent CSFV strains
Alfort/187 (19) and ALD (14) and vaccine strains GPE (14), derived from strains ALD and C (23). The amino acids at the positions where
substitutions were found in C1.1.1 and CoBrB 476R are shown in bold type.
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for one pig (pig 4056), which died of CSF (day 14) before
developing antibodies against E2. Another pig (pig 4054) in
this group, which had recovered from CSF, died before the end
of the trial for unknown reasons. Virus C1.1.1/CoBrB (Npro-
C-Erns-E1) (group E), carrying only the 2 amino acids in Erns
that originate from the virulent CoBrB 476R, did not cause CSF
and is avirulent in pigs (Table 1).
Genetic analysis of in vivo-generated virus. Blood samples
taken from pigs were used to infect SK6 cells, and after 2 days,
RNA was extracted from these cells and used to determine the
sequence of the regions containing mutations. For all viruses,
the sequence determined matched the original genotype of the
virus administered to the pig. These results showed that rep-
lication of these recombinant viruses did not induce genetic
changes (such as reversion) in the sequenced regions. How-
ever, as in a previous study (12), a minority of revertants were
found in blood from a pig infected with CoBrB 476R. The
reversion consists of an amino acid substitution in Erns at
residue position 476 from an Arg to a Ser, which reflects the
phenotypical change from an HS-dependent virus to an HS-
independent virus in vitro. This change had no effect on viru-
lence in pigs (12). The amino acid 476S is the predominant
variant found in blood from a pig infected with Brescia, pig
456610. Therefore, in further experiments, the CoBrB 476S
variant was used as the parental virulent virus instead of
CoBrB 476R virus.
Construction and characterization of chimeric viruses de-
rived from C1.1.1 and CoBrB 476S with adaptive mutations in
Erns and E2. The only difference between CoBrB 476R/C1.1.1
and C1.1.1/CoBrB (Npro-C-Erns-E1) is a single amino acid
substitution at position 710 (L3H). Because virus CoBrB
476R/C1.1.1 caused CSF (in two of three pigs) and virus C1.1.1/
CoBrB (Npro-C-Erns-E1) was avirulent, the results from ani-
mal experiment 1 indicate that a single amino acid substitution
at position 710 (L3H) may be involved in the virulence of strain
Brescia. Therefore, the possible role of the adaptive amino
acid mutation 710L3H in virulence was investigated further.
Therefore, two new full-length cDNAs were constructed.
The first full-length cDNA [pflCoBrB 476S/C1.1.1(E2-p7-
pNS2-3)] contained the adaptive amino acid mutation at po-
sition 710 in the virulent background of CoBrB 476S (Fig. 3).
The second full-length cDNA [pflCoBrB/C1.1.1 (Npro-C-Erns-
E1)] contained three adaptive amino acid mutations in Erns
(276R, 476R, and 477I) compared to the CoBrB 476S variant.
Virus stocks (p2) of CoBrB 476S and CoBrB/C1.1.1 (Npro-C-
Erns-E1) were produced as described above. The introduced
mutations were confirmed by sequence analysis of the Erns and
E2 genomic regions of these recombinant viruses (p2 stocks).
FIG. 3. Schematic representation of full-length cDNA constructs of parent CSFV strains CoBrB (shaded bars) and C1.1.1 (white bars), and
chimeric viruses derived from these strains. The genome organization and the name of the virus (exchanged proteins in parentheses) are shown.
The original amino acids in CoBrB and the adaptive amino acid mutations in C1.1.1 and chimeric viruses are shown, and localization (lollypops)
is indicated. When a fusion of C1.1.1 and CoBrB resulted in a hybrid protein, this was indicated by a prime after the name of the protein.
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The Ser3Arg mutation at position 476 in Erns reflects the
phenotypical change from an HS-independent virus to an
HS-dependent virus. Therefore, virus stocks (p2) of CoBrB
476S, CoBrB 476S/C1.1.1 (E2-p7-pNS2-3), C1.1.1/CoBrB,
and CoBrB/C1.1.1 (Npro-C-Erns-E1) were tested for inhibi-
tion of infection by heparin. Infection of SK6 cells with C1.1.1/
CoBrB and CoBrB/C1.1.1 (Npro-C-Erns-E1) was inhibited by
100% by 225 g of heparin per ml. In contrast, infection of
SK6 cells with CoBrB 476S and CoBrB 476S/C1.1.1 (E2-p7-
pNS2-3) was not significantly affected by heparin (Table 2).
When SK6 cells were grown under a methylcellulose overlay
medium, the diameters of plaques of both CoBrB 476S variants
(S-ST) were two to three times larger than those of the plaques
from both C1.1.1/CoBrB and CoBrB/C1.1.1 (Npro-C-Erns-E1)
(R-RI). Furthermore, the titers of p2 virus stocks measured on
SK6 cells were about 100-fold lower for CoBrB 476S and
CoBrB 476S/C1.1.1 (E2-p7-pNS2-3) than for CoBrB/C1.1.1
(Npro-C-Erns-E1) and C1.1.1/CoBrB (4.5 and 4.0 log10 PFU/ml
for the S-ST variants versus 6.7 and 6.3 log10 PFU/ml for the
R-RI variants, respectively). These results clearly showed that
infection of SK6 cells with the R-RI variants occurred by an
HS-dependent mechanism and that infection with S-ST vari-
ants occurred by an HS-independent mechanism. The 710L3H
mutation in the S-ST and R-RI variants reflects the phenotyp-
ical change from nonbinding (710L) to binding (710H) to MAb
V6. After immunostaining, expression of CSFV E2 could be
detected with MAb V6 in SK6 cells infected with CoBrB 476S/
C1.1.1 (E2-p7-pNS2-3) and C1.1.1/CoBrB. In contrast, no E2
was detected with MAb V6 after staining of SK6 cells infected
with the virus variants that carried a Leu at position 710,
TABLE 1. Serological and clinical findings after inoculation of pigs with chimeric viruses derived from
C1.1.1 and CoBrB 476R in animal experiment 1
Groupa Virus Animalno.
Clinical findings Serological findings (% inhibition) byE2 ELISA f on d.p.i.: Viremia
g on d.p.i.:
Feverb L/Tc IFT(T K S I)d
Death
(d.p.i.)e 0 7 14 21 23 0 2 4 7 9 11 14 16 18 21 23
A C1.1.1 4051  /   0 0 90 102 102           
4052 3 (5) /   0 0 91 101 102           
4053  /   0 0 96 102 102           
B CoBrB 476R 4060 11 (3) /   (22) 0 0 0 0          
4061 11 (3) /   (14) 0 0 0        
4062 12 (4) /   0 0 0 0 0          
C CoBrB 476R/C1.1.1 4057 8 (4) /   (14) 0 0      
4058  /   0 0 30 92 99           
4059 9 (7) /   (17) 0 0 0      
D C1.1.1/CoBrB 4054 4 (4) /   (18) 0 0 97        
4055 7 (4) /   0 0 101 102 102           
4056 8 (4) / h  (14) 0 0      
E C1.1.1/CoBrB
(Npro-C-Ems-E1)
4066  /   0 0 51 100 101           
4067 1 (4) /   0 0 33 95 100           
4068  /   0 0 18 89 97           
a Three pigs in each group were inoculated intranasally once with 105 TCID50 of each virus.
b Fever defined as a body temperature of 40°C. The number of days with fever is shown. The day the fever began is shown in parentheses. , no fever.
c Leukopenia (L) and thrombocytopenia (T) are defined as cell/platelet counts below 8  106 cells/ml and 200  106 cells/ml, respectively.
d Immunofluorescence technique (IFT) for detection of viral antigen in cryostat sections from tonsils (T), kidney (K), spleen (S), and ileum (I) at death.
e Pigs were either found dead or killed when moribund (). The time of death (in days p.i. [d.p.i.]) is shown in parentheses. , animal did not die.
f The E2 ELISA specifically detects antibodies against CSFV.
g Isolated leukocyte samples were incubated on SK6 cells for detection of virus by using an immunoperoxidase monolayer assay.
h A few crypts in tonsils were found positive.
TABLE 2. Characterization of clinical samples
Virus or
animal no.a Sample
b Titer
(SK6/Macr)c
% Inhibition
by heparind
Plaque
sizee
CoBrB 476S SK6 4.5/6.8 0 Large
5012 Tonsil 6.0/7.1 40 Large
Kidney 5.7/6.9 40 Large
Blood 6.3/6.6 65 Large
CoBrB 476S/C1.1.1
(E2-p7-pNS2-3)
5016
SK6 4.0/6.3 5 Large
Tonsil 6.4/7.3 55 Large
Kidney 5.0/6.6 55 Large
Blood 4.9/5.7 80 Large
C1.1.1/CoBrB SK6 6.7/5.9 100 Small
5020 Tonsil NDf ND ND
Kidney ND ND ND
Blood 1.0/2.3 100 Small
CoBrB/C1.1.1
(Npro-C-Erns-E1)
5024
SK6 6.3/6.2 100 Small
Tonsil 7.5/6.9 95 Small
Kidney 5.5/4.8 100 Small
Blood 4.3/4.4 100 Small/largeg
a In vitro (SK6)- or in vivo-generated (animal number) virus.
b Tonsil and kidney samples were prepared postmortem. EDTA-treated blood,
taken at day 14 p.i., was tested.
c Titers (log10 PFU per milliliter) were measured in a plaque assay using SK6
cells or lung macrophages (Macr).
d Percent inhibition of infection of SK6 cells by 225 g of heparin per ml.
e Relative plaque size observed after 2 days of growth in a plaque assay using
SK6 cells. Cells were not treated with heparin.
f ND, not determined.
g In the blood from this animal, approximately 1:100 plaques was a large-
plaque variant.
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despite the detection of E2 expression in duplicate monolayers
after staining with MAb V3 (conserved among pestiviruses).
Virulence of chimeric viruses derived from C1.1.1 and
CoBrB 476S with adaptive mutations in Erns and E2. To ana-
lyze the effect of the adaptive 710L3H amino acid mutation on
virulence in pigs, animal experiments were conducted. Pigs
were infected intranasally according to the regimen described
in Materials and Methods, and the results are shown in Ta-
ble 3.
All pigs infected with CoBrB 476S (group A) and CoBrB
476S/C1.1.1 (E2-p7-pNS2-3) (group B), in which the Leu at
position 710 was replaced by His (adaptive amino acid muta-
tion), rapidly developed fever (40°C) at 2 or 3 days p.i. that
lasted for more than 10 days, and showed symptoms of acute
CSF (Table 3). The uninfected sentinels that were placed in
the stable of the infected animals of groups A and B at 24 h p.i.
to allow contact exposure developed fever for a period of more
than 10 days and also became seriously ill. All animals devel-
oped leukopenia and thrombocytopenia and were viremic from
day 4 p.i. (infected pigs) or from day 7 p.i. (sentinels) onwards.
Pigs were killed when moribund. After slaughter, viral antigen
was detected in tonsil, spleen, kidney, and ileum tissue sam-
ples. With the exception of one pig, no E2 antibodies were
detected in the serum samples collected from pigs during the
trial and when they were slaughtered. Pig 5019, infected with
CoBrB 476S/C1.1.1 (E2-p7-pNS2-3) (group B), developed an-
tibodies against E2, and the virus levels in blood samples dis-
appeared after 11 days. After slaughter, viral antigen was de-
tected only in a few crypts of the tonsils and in spleen and
ileum tissue samples.
The pigs infected with C1.1.1/CoBrB (group C), in which the
adaptive amino acid mutations in Erns (276R, 476R, and 477I)
and E2 (710H) were introduced into CoBrB 476R, showed no
signs of CSF (Table 3). Only two pigs developed fever for a
short period (3 days). Virus was detected in blood samples of
all pigs in this group only at day 7 p.i. (infected pigs) and at day
14 p.i. (sentinel pig). All pigs developed antibodies against E2,
and after slaughter, viral antigen was detected only in a few
crypts in the tonsils of pigs 5020c and 5023 and the spleen of
pig 5022.
Virus CoBrB/C1.1.1 (Npro-C-Erns-E1) (group D), in which
the adaptive amino acid mutations in Erns (276R, 476R, and
477I) were introduced into virulent CoBrB 476S, exhibits the
same level of virulence as viruses CoBrB 476S (group A) and
CoBrB 476S/C1.1.1 (E2-p7-pNS2-3) (group B), except for a
delayed onset of fever and spreading to the sentinel pig (Table
3). In conclusion, the 710L (wild type) or 710H (adaptive mu-
tation in C1.1.1) in CoBrB 476S variants does not seem to affect
virulence in pigs, whereas the CoBrB/C1.1.1 (Npro-C-Erns-E1)
variant with 710L is virulent but with a delayed onset of disease.
Interestingly, the C1.1.1/CoBrB (group C) variant with 710H
does not seem to be virulent; however, very mild symptoms in
a few pigs were observed (mild fever and viremia).
Genetic analysis of in vivo-generated viruses. The virus ti-
ters in blood samples, taken from pigs, were determined in a
plaque assay to determine the plaque size after 2 days of
TABLE 3. Serological and clinical findings after inoculation of pigs with chimeric viruses derived from
C1.1.1 and CoBrB 476S in animal experiment 2
Groupa Virus Animalno.
Clinical findings Serological findings (% inihibition) byE2 ELISA f on d.p.i.: Viremia
g on d.p.i.:
Feverb L/Tc IFT(T K S I)d
Death
(d.p.i.)e 0 7 14 21 0 2 4 7 9 11 14 16 18 21 23
A CoBrB 476S 5012c 13 (5) /   (16) 0 0 0        
5013 13 (2) /   (14) 0 0 11       
5014 13 (3) /   (14) 0 0 43       
5015 14 (2) /   (14) 0 0 0       
B CoBrB 476S/C1.1.1
(E2-p7-pNS2-3)
5016c 10 (7) /   (16) 0 0 0        
5017 10 (2) /   (11) 0 0      
5018 6 (3) /   (9) 0 0    
5019 10 (3) / h  (16) 0 0 82        
C C1.1.1/CoBrB 5020c 3 (11) / h  0 0 0 97           
5021  / i  0 0 98 101           
5022 1 (7) / h, i  0 0 100 100           
5023  / i  0 0 98 101           
D CoBrB/C1.1.1
(Npro-C-Erns-E1)
5024c 7 (12) /   (18) 0 0 0         
5025 10 (5) /   (15) 0 0 0       
5026 7 (5) /   (11) 0 0      
5027 9 (5) /   (18) 0 0 0         
a Three pigs in each group were inoculated intranasally once with 105 TCID50 of each virus. The sentinal (contact exposure) animals (c) were placed in each group
24 h after inoculation of the other animals.
b Fever defined as a body temperature of 40°C. The number of days with fever is shown. The day the fever began is shown in parentheses. , no fever.
c Leukopenia (L) and thrombocytopenia (T) are defined as cell/platelet counts below 8  106 cells/ml and 200  106 cells/ml, respectively.
d Immunofluorescence technique (IFT) for detection of viral antigen in cryostat sections from tonsils (T), kidney (K), spleen (S), and ileum (I) at death.
e Pigs were either found dead or killed when moribund (). The time of death (in days p.i. [d.p.i.]) is shown in parentheses. , animal did not die.
f The E2 ELISA specifically detects antibodies against CSFV.
g Isolated leukocyte samples were incubated on SK6 cells for detection of virus by using an immunoperoxidase monolayer assay.
h A few crypts in tonsils were found positive.
i In some organ samples taken from the ileum, autolysis was found.
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growth under a methylcellulose overlay medium. In wells con-
taining blood samples, taken short before death (14 days p.i.),
from pigs infected with CoBrB 476S or CoBrB 476S/C1.1.1 (E2-
p7-pNS2-3), all plaques were large and similar in size to
plaques formed by CoBrB 476S or CoBrB 476S/C1.1.1 (E2-p7-
pNS2-3) produced in SK6 cells (Table 2). In wells containing
blood samples taken from pigs infected with C1.1.1/CoBrB at
7 days p.i. (pig 5021) and 14 days p.i (pig 5020), all plaques
were small and similar in size to plaques formed by C1.1.1/
CoBrB produced in SK6 cells.
The blood samples from pig 5012 (CoBrB 476S), pig 5016
(CoBrB 476S/C1.1.1 (E2-p7-pNS2-3) and pig 5020 (C1.1.1/
CoBrB), which were analyzed above for plaque phenotype,
were used to infect SK6 cells. After 2 days of growth under a
methylcellulose overlay medium, RNA was extracted from
these cells and used to determine the sequences of the Erns,
E1, and E2 genes. For all these reisolated viruses, the Erns, E1,
and E2 sequences were identical to the sequences of the vi-
ruses administered to the pigs. These results showed that rep-
lication of CoBrB 476S, CoBrB 476S/C1.1.1 (E2-p7-pNS2-3),
and C1.1.1/CoBrB did not induce genetic changes in the en-
velope proteins. However, when the virus titers in blood sam-
ples from pig 5026 and 5024 infected with CoBrB/C1.1.1
(Npro-C-Erns-E1), taken on day 11 p.i. and day 18 p.i, respec-
tively, were determined in a plaque assay (with 225 g of
heparin per ml), large plaques were detected (about one large
plaque found for every 20 small plaques), whereas CoBrB/
C1.1.1 (Npro-C-Erns-E1) virus produced in SK6 cells formed
only small plaques. Large plaques were also detected in blood
samples from the two other pigs from this group. However, no
large plaques were detected when virus titers of tissue samples,
collected from pigs 5024 and 5026 or from the other two pigs,
were determined in the presence of heparin. For further anal-
ysis, virus isolated from a blood sample (18 days p.i.) from pig
5024 was cloned through endpoint dilution.
To favor infection by virus variants with a large-plaque phe-
notype, endpoint dilution was performed in medium contain-
ing 225 g of heparin per ml. Of 23 cloned viruses analyzed,
one had a large-plaque phenotype. The sequences of the Erns,
E1, and E2 genes of this cloned virus, isolated from a blood
sample from pig 5024 (virus 5024#18rev), were analyzed, to-
gether with a small-plaque-phenotype virus isolated from the
same blood sample (virus 5024#17wt). Sequence analysis of the
large-plaque-phenotype virus 5024#18rev showed that the Arg
at position 476 in the polyprotein was changed to a His. There-
fore, in a blood sample from pig 5024, which was infected
through contact exposure with pigs infected with CoBrB/C1.1.1
(Npro-C-Erns-E1), a minority of a large-plaque-phenotype vi-
rus variant [CoBrB/C1.1.1 476H (Npro-C-Erns-E1)] was found.
Sequence analysis of the cloned small-plaque-phenotyped vi-
rus 5024#17wt showed that this virus was identical to the virus
administered to the pig. As observed for the HS-independent
CoBrB 476S virus, additional passages in SK6 cells converted
this large-plaque-phenotype CoBrB ErnsR-HI E2L variant to a
small-plaque variant (results not shown).
Surface properties of in vivo- and in vitro-generated viruses.
Virus titers in organ suspensions and blood samples were de-
termined in a plaque assay with and without 225 g of heparin
per ml. In Table 2, the results of these experiments are pre-
sented for pigs 5012 (CoBrB 476S), 5016 [CoBrB 476S/C1.1.1
(E2-p7-pNS2-3)], 5020 (C1.1.1/CoBrB), and 5024 [CoBrB/
C1.1.1 (Npro-C-Erns-E1)]. Test results obtained with other
samples taken from the pigs of the different groups were not
significantly different from those presented here. All clinical
samples from pigs 5012 and 5016 (CoBrB 476S viruses) formed
only large plaques on SK6 cells, which were similar in size to
those for in vitro-produced viruses. Only one blood sample (14
days p.i.) from pig 5020 (C1.1.1/CoBrB) was analyzed, because
no virus was isolated from organ samples from this pig and the
other pigs in this group. Virus from this blood sample formed
only small plaques on SK6 cells. Blood samples, taken from pig
5024, formed small and large plaques. When the virus titer for
blood from this pig was determined in the absence of heparin,
1 of 100 plaques was large, representing the revertant of
CoBrB/C1.1.1 (Npro-C-Erns-E1). Virus from the other organ
samples of this pig and the SK6 cells infected with CoBrB/
C1.1.1 (Npro-C-Erns-E1) tested formed only small plaques.
Infection of SK6 cells with virus samples taken from pigs
5020 (C1.1.1/CoBrB) and 5024 [CoBrB/C1.1.1 (Npro-C-Erns-
E1)] was almost completely inhibited (95 to 100%) by 225 g
of heparin per ml. Infection of SK6 cells with virus samples
from pigs 5012 (CoBrB 476S) and 5016 [CoBrB 476S/C1.1.1
(E2-p7-pNS2-3)] showed 40 to 65% inhibition for CoBrB 476S
and 55 to 80% inhibition for CoBrB 476S/C1.1.1 (E2-p7-pNS2-
3), whereas infection with both viruses produced in SK6 cells
was not inhibited.
From the in vitro-produced virus and reisolated viruses from
clinical samples, virus titers were determined in a plaque assay
after growth for 1 day under a methylcellulose overlay me-
dium. Except for virus isolated from the tonsil of pig 5024,
lower virus titers were detected in organ and blood samples for
both R-RI variants than in organs and blood samples isolated
from pigs infected with both S-ST variants, when samples were
analyzed in a plaque assay using lung macrophages. Moreover,
for C1.1.1/CoBrB, virus was isolated from the blood of pig 5020
only on one day (14 days p.i.). Note that the virus titers of
organ samples and for in vitro-produced CoBrB 476S variants
are about 10-fold lower in assays using SK6 cells than the titers
in assays using macrophages.
Recently, Hulst et al. (12) found that ConA binding to N-
linked glycans exposed on the surfaces of virions is responsible
for the observed stimulation or inhibition of infection of CSFV
strain Brescia. ConA is a lectin that specifically binds with high
affinity to terminal mannose (and with less affinity to glu-
cosamine) residues of N-linked glycosyl groups. Most likely,
ConA masks negatively or positively charged domains on the
surfaces of CSFV particles, leading to either a more (stimula-
tion) or less (inhibition) effective binding of virions to the
highly negatively charged sulfate-rich clusters of HS. There-
fore, we used ConA binding to demonstrate possible differ-
ences in the surface structure of in vitro-generated viruses.
Infection on SK6 cells was inhibited for both CoBrB R-RI
variants in a dose-dependent manner (Fig. 4). Virus CoBrB/
C1.1.1 (Npro-C-Erns-E1) was inhibited 4-fold by a concentra-
tion of 50 g of ConA, whereas virus C1.1.1/CoBrB was inhib-
ited 15-fold by the same concentration of ConA. Infection on
SK6 cells was stimulated for both CoBrB 476S variants. Virus
CoBrB 476S was stimulated 1,000-fold by a concentration of
12.5 g of ConA per ml, whereas virus CoBrB 476S/C1.1.1
(E2-p7-pNS2-3) was stimulated 35-fold by a concentration of
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6.25 g of ConA per ml. The significantly higher stimulation of
infection observed for CoBrB 476S compared to that for CoBrB
476S/C1.1.1 (E2-p7-pNS2-3) indicated that these CoBrB 476S
genotypes have different surface properties, although the only
difference is the L3H mutation at position 710. In the same
way, but to a lesser extent, a slightly higher inhibition of infec-
tion was observed for CoBrB/C1.1.1 (Npro-C-Erns-E1) than for
C1.1.1/CoBrB.
Ratio of secreted virus to cell-associated virus. We deter-
mined the ratio of secreted virus to cell-associated virus on
SK6 cells for all CoBrB variants to ascertain whether the vir-
ulence of the variants tested correlated with the particle re-
lease from SK6 cells. For CoBrB 476S and CoBrB 476S/C1.1.1
(E2-p7-pNS2-3), approximately 1.5 times more virus particles
were present in the culture medium than in the cell fraction
(Fig. 5). For CoBrB/C1.1.1 (Npro-C-Erns-E1) and C1.1.1/
CoBrB, about two times more virus was present in the cellular
fraction than in the culture medium.
Virus neutralization index. Appropriate dilutions of MAb
V4 (directed against the conserved A domain of E2), MAb V6
(directed against domain B of E2), and a serum sample from a
C1.1.1/CoBrB-infected pig (PabR-RI H) were incubated with in
vitro- and in vivo-generated viruses to determine the reduction
of the virus titers on SK6 cells through neutralization with
MAbs or PAbs (Table 4). MAb V4 neutralized all in vitro-
generated viruses by 3.5 log units or more. As expected, MAb
V6 neutralized CoBrB 476S/C1.1.1 (E2-p7-pNS2-3) and
C1.1.1/CoBrB by 2.6 and 3.0 log units, respectively, whereas
CoBrB 476S and CoBrB/C1.1.1 (Npro-C-Erns-E1) were neutral-
ized only by 0.75 and 0.25 log unit, respectively. Interestingly,
serum PabR-RI H, which is a PAb serum with antibodies against
all viral proteins, showed lower neutralizing indices for the
heterologous viruses CoBrB 476S (2.0 log units) and CoBrB/
C1.1.1 (Npro-C-Erns-E1) (1.5 log units) than for CoBrB 476S/
C1.1.1 (E2-p7-pNS2-3) (3.4 log units) and C1.1.1/CoBrB (3.25
log units), indicating that the 710H3L mutation is also impor-
tant for recognition in the whole spectrum of antibodies.
To a certain extent, the same results were obtained for the in
vivo-generated viruses. Except for C1.1.1/CoBrB, which could
not be tested accurately because of low virus titers in the blood
samples, all variants were efficiently neutralized by MAb V4
(reduced by 5.0 log units). MAb V6 neutralized CoBrB 476S/
C1.1.1 (E2-p7-pNS2-3) by 2.5 log units, whereas CoBrB/
FIG. 4. Stimulation or inhibition of infection by ConA. Virus variants CoBrB 476S, CoBrB 476S/C1.1.1 (E2-p7-pNS2-3), C1.1.1/CoBrB, and
CoBrB/C1.1.1 (Npro-C-Erns-E1) (produced in SK6 cells) were preincubated with different concentrations of ConA for 30 min at 37°C. SK6 cells
in 2-cm2 tissue culture wells were preincubated with EMEM with 300 g of heparin per ml for 30 min at 37°C and then infected with virus. After
the virus was removed and the cells were washed, the cells were incubated with 100 mM methyl--D-mannopyranoside for 30 min at 37°C.
Subsequently, they were washed and supplied with overlay medium and stained after 24 h. Each value is the mean number of plaques calculated
from two independent observations.
FIG. 5. Ratio of cell-associated virus to secreted virus. SK6 cells
grown in 24-well plates were infected with virus variants CoBrB 476S,
CoBrB 476S/C1.1.1 (E2-p7-pNS2-3), C1.1.1/CoBrB, and CoBrB/C1.1.1
(Npro-C-Erns-E1) (produced on SK6 cells) at an MOI of 1. After
infection for 30 min at 37°C, virus was removed, and cells were washed.
At 2 days p.i., 1 ml of supernatant was collected and stored at 70°C.
One milliliter of culture medium was added to the cells before freeze-
thawing twice at 70°C. Samples were titrated on SK6 cells in 24-well
plates. The ratio of secreted virus to cell-associated virus was deter-
mined in a plaque assay and calculated by the following formula:
ratio  log10 PFU of cell-associated virus  log10 PFU of secreted
virus. An average ratio value for all tested viruses was determined from
two experiments.
TABLE 4. Virus neutralization of in vitro- and in vivo-generated
chimeric viruses derived from C1.1.1 and CoBrB 476S
Virus
Neutralization of
SK6-generated virusa
Neutralization of in
vivo-generated virusa
V4 V6 PabR-RI V4 V6 PabR-RI H
CoBrB 476S 4.0 0.8 2.0 5.0 0.0 1.5
CoBrB 476S/C1.1.1
(E2-p7-pNS2-3)
3.5 2.6 3.4 4.8 2.5 5.7
CoBrB/C1.1.1
(Npro-C-Erns-E1)
4.8 0.3 1.5 4.8 0.3 0.8
C1.1.1/CoBrB 5.7 3.0 3.3 NDb ND ND
a Neutralization of in vitro (produced on SK6)- or in vivo-generated chimeric
viruses derived from C1.1.1 and CoBrB 476S. Blood samples from animals 5012
(CoBrB 476S), 5016 [CoBrB 476S/C1.1.1 (E2-p7-pNS2-3)], and 5024 [CoBrB/
C1.1.1 (Npro-C-Erns-E1)] were collected, and the titers of virus from the blood
samples were determined on SK6 cells with or without neutralizing MAbs or
PAbs. The values represent the log TCID50 per milliliter reduction of CSFV
titers due to the presence of MAbs or PAbs. Neutralizing MAbs and PAbs are as
follows: MAb V4 (directed against the conserved A domain of E2), MAb V6
(directed against domain B of E2), and a serum sample from a CoBrB EmsR-RI
E2H-infected pig (PabR-RI H).
b ND, not done because the virus titers in blood samples from pigs infected
with this virus were too low.
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C1.1.1 (Npro-C-Erns-E1) was neutralized by 0.3 log unit and
CoBrB 476S was not neutralized at all. Regarding the 710H3L
mutation, even clearer results were obtained when the serum
Pab
R-RI H
was used to determine neutralizing indices for in vivo-
generated viruses. Serum from a C1.1.1/CoBr-infected pig was
able to neutralize virus in blood from pig 5016 [CoBrB 476S/
C1.1.1 (E2-p7-pNS2-3)] by 5.7 log units, whereas low neutral-
izing indices were obtained for pig 5012 (CoBrB 476S) and pig
5020 [CoBrB/C1.1.1 (Npro-C-Erns-E1)]. These results suggest
that besides the importance of 710H as an epitope for neutral-
izing antibodies, this amino acid residue is also crucial for the
structure of E2.
DISCUSSION
This study reports on the mechanism of attenuation of lab-
oratory-derived CSFV by host cell adaptation and defines mo-
lecular determinants for the loss of the capacity of CSFV strain
Brescia variants to produce disease in pigs. Recently, it was
demonstrated that limited cultivation of CSFV on porcine kid-
ney cells selects variants that attach to the surfaces of cells by
interaction with the membrane-associated HS. A Ser-to-Arg
change in the C terminus of Erns at position 476 in the ORF of
CSFV strain Brescia is responsible for selection of these HS-
binding variants (11). However, this Ser-to-Arg change
(CoBrB 476S and CoBrB 476R) did not reduce virulence in pigs
(12). The selection of CSFV variants with an altered virulence
phenotype by serial passage in porcine kidney cells had been
demonstrated earlier for strain Brescia (41). They showed that
an extensively passaged (31 times) and cloned virus C1.1.1 was
avirulent in pigs. Therefore, we determined the consensus se-
quences of the genetically closely related strains, virulent
CoBrB 476R and avirulent C1.1.1, which were both isolated
from the same blood sample of a pig infected with Brescia. We
found nine adaptive amino acid changes, besides 20 silent
mutations, in C1.1.1. Of the nine adaptive amino acid changes,
three were located in the structural region, and the other six
were located in the nonstructural region.
In the first animal experiment, we focused on these nine
adaptive amino acid mutations by making chimeric C1.1.1/
CoBrB 476R virus variants, in which either the structural or
nonstructural region was exchanged. A minor role for the
adaptive amino acid mutations in the nonstructural region on
virulence was observed, although some interesting amino acid
changes are present. Amino acid 1971P of C1.1.1 is not located
in any of the known protease/ATPase/helicase motifs of NS3
(8), but adaptive amino acid mutation 1915S is located 2 amino
acids downstream of the DEYH sequence (also known as the
Walker motif or motif II [36]), one of the seven conserved
motifs that are characteristic for RNA helicases of the DExH
type. Grassmann et al. (8) showed that mutations of the third
position in the DEYH motif permitted replication, although at
a lower level than that of wild-type RNA. In vitro studies with
the purified mutant NS3 proteins revealed a significantly im-
paired helicase activity for the motif II substitutions. Although
the adaptive amino acid mutation 1915S in not found in other
virulent and avirulent CSFV strains, further in vitro studies
should be performed to determine the influence of this muta-
tion in the vicinity of the Walker motif on helicase or nucleo-
tide triphophatase activity. The same holds true for the adap-
tive amino acid mutations 3419I and 3858A in NS5b, which are
not located in any of the known RNA-dependent RNA poly-
merase motifs (17). These amino acids and 2638V in NS4b and
2846C in NS5a may influence virulence by affecting the stability
of NS2-3, NS4a, NS4b, NS5a, and NS5b in the replication
complex. Mittelholzer et al. (21) found no correlation between
RNA levels in vitro and virulence in a study of CSFV strains
with different degrees of virulence. Their results suggest that
mutations located in the nonstructural region that are involved
in replication (such as NS3 and NS5b) are not determinants for
virulence in the CSFV strains they tested.
The first animal experiment revealed a possible role for the
His residue at position 710 in the ORF of CSFV, since virus
CoBrB 476R/C1.1.1 was moderately virulent and C1.1.1/CoBrB
(Npro-C-Erns-E1) was not virulent. Further studies showed
that the 710H by itself was not enough to reduce virulence in
pigs, but together with adaptive amino acid changes in Erns
(276R, 476R, and 477I), it did reduce virulence. The 710L3H
mutation has already been characterized as a MAb-resistant
mutation for MAb V6 (MAb V6 epitope located in the non-
conserved B domain of E2) (34). Besides an important neu-
tralization site, it also reflects a structural change in E2 that is
probably crucial for the function(s) of E2 in vivo.
The most dramatic change in Erns is the 476S3R mutation,
which reflects the adaptation to SK6 cells from an HS-inde-
pendent virus to an HS-dependent virus (11). Binding of bac-
ulovirus-expressed Erns recombinant proteins (S-ST, S-RT,
R-RI, S-RI, R-RT, and R-ST, representing the amino acid
combinations at positions 276, 476, and 477 in Erns) to immo-
bilized heparin-HS-type polysaccharide chains by heparin-
Sepharose chromatography showed that an Arg at position 476
increased the affinity of heparin significantly. Furthermore,
276Arg in the N terminus of Erns and 477Ile, which is involved in
the recognition of antigenic sites (43), adjacent to 467Arg in
Erns in R-RI further increased the affinity of binding of Erns to
heparin (M. Hulst, personal communication). Amino acid 276
(S for CoBrB and R for C1.1.1) is located in the N terminus of
Erns, upstream of the first RNase domain of Erns (9). The role
of this adaptive amino acid residue 276R in Erns, which is
conserved among virulent and avirulent CSFV strains and
which eliminates a potential N-linked glycosylation site (NXS)
(11, 16), was not investigated in vivo. However, studies with
baculovirus-expressed Erns recombinant proteins (S-ST, S-RT,
R-RI, S-RI, R-RT, and R-ST) revealed that this potential
glycosylation site was not glycosylated in insect cells (M. Hulst,
personal communication).
For many viruses (reference 29 and references therein), HS-
mediated entry is the first step in the infection process, fol-
lowed by interaction of viral proteins with other cellular me-
diators (secondary receptors) for adhesion and penetration.
Moreover, for foot-and-mouth disease virus, simian virus,
Murray Valley encephalitis virus, and Japanese encephalitis
virus, it was shown that HS-dependent virus variants, selected
in cell culture, are less virulent than their HS-independent
counterparts. It was speculated that HS binding in vivo is a
disadvantage for the virus, at least for those that spread through
the circulation system and do not spread by cell-to-cell contact.
Culture-adapted virus variants are rapidly cleared by tissue HS,
which is sulfated to a much higher extent than endothelial HS
is (29). However, it was shown for CSFV that the Ser-to-Arg
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change, from an HS-independent virus to an HS-dependent
virus, did not reduce virulence in vivo (12). Our results with the
R-RI variants, with a relatively high affinity for heparin com-
pared to that of CoBrB 476S, indicate that spreading of these
viruses through the circulation system was reduced. A delayed
onset of disease was observed for the animals infected with the
CoBrB/C1.1.1 (Npro-C-Erns-E1) virus, and the spread to a
contact-exposed animal was also delayed compared to the
CoBrB 476S virus. This would indeed favor the hypothesis that
HS binding in vivo is a disadvantage for the virus. However, for
CSFV, it was shown that an HS-independent virus generated in
vivo is still able to use HS as an attachment site for primary
swine kidney cells (12), probably due to heterogeneity in sur-
face properties of virus particles. Maybe the CoBrB 476S vari-
ant uses specific HS motifs displayed on specific host cells or
more specific receptors are involved, leading to selection or
infection of specific host cells. Therefore, even if HS does not
serve as an entrance gate, this may direct the viral pathogen to
certain sites where the preferential HS features are displaced,
and this can make the difference between easy or more difficult
access.
Growth of the HS-dependent variant and CoBrB/C1.1.1
(Npro-C-Erns-E1) in pigs yielded revertants with a character-
istic large-plaque phenotype. However, the ratio of revertant
to nonrevertant phenotypes remained low (	1% on the basis
of plaque size) from virus from blood samples, indicating that
the pathogenesis in these animals was due to growth of the
HS-dependent virus rather than that of the revertant virus.
Moreover, nonrevertant viruses were also found predomi-
nantly in blood samples from the sentinel pig (ratio of rever-
tant to nonrevertant phenotypes of	1% on the basis of plaque
phenotype), indicating that growth of this virus was responsible
for the pathogenesis in this pig. Revertants with an amino acid
change R3H at position 476 in Erns were isolated from blood
samples from infected pigs, whereas no revertants were iso-
lated from tonsil, spleen, kidney, and ileum tissue samples.
This reversion reflected the change from an HS-dependent
virus to an HS-independent virus. This phenomenon was al-
ready observed in a previous study (12), in which a low level of
revertants with a large-plaque phenotype was found in blood
samples from one of three pigs infected with CoBrB 476R.
Analysis of this revertant virus revealed 467Ser instead of
467Arg. This change had no effect on the virulence of this virus
in pigs.
The results presented here suggest that the attenuation of
cell-adapted CSFV strain Brescia is correlated with the acqui-
sition of positively charged amino acid residues in glycopro-
teins Erns and E2. The ratio of secreted virus particles (cell-
free) to cell-associated virus particles in SK6 cells correlated
with the overall (or local) charge of the virions (from positive
to negative, R-RI H [0.55], R-RI L [0.6], S-ST H [1.3] and S-ST
L [1.7] [ratios shown in brackets]). In contrast to the results of
Mittelholzer et al. (21), these results suggested that reduced
particle release is not always correlated with the virulence of
CSFV strains. According to our standards, CoBrB/C1.1.1
(Npro-C-Erns-E1) could be classified as virulent with delayed
onset of disease compared to highly virulent CoBrB 476S,
whereas a reduced particle release on SK6 cells was observed.
Inhibition or stimulation of infection of CSFV variants on SK6
cells with ConA also correlated with the overall (or local)
charge of the virions (from positive to negative, R-RI H, R-RI
L, S-ST H, and S-ST L). The observed differences in neutral-
izing indices caused by the adaptive amino acid change (L3
H) at position 710 in E2 suggest that this mutation plays a
crucial role in the structure of E2. Structural changes and/or
the acquisition of positively charged amino acids of cell-
adapted CSFV variants might have an synergistic effect with
the adaptive mutations in Erns and E2, because of the recently
shown interaction of Erns and E2 in the virion through a non-
covalent interaction (18).
The virulence of CSFV seems to be determined in a rather
complex manner. First, the acquisition of positively charged
amino acids in Erns, which lead to an HS-independent virus, is
not enough to reduce virulence in pigs. HS binding in vivo is
considered to be a disadvantage for the virus, but earlier results
indicated that this is not completely true for CSFV (12). How-
ever, the disease spread less in pigs infected with CoBrB R-RI
variants (HS) than in pigs infected with CoBrB S-ST variants
(HS). This suggests that HS binding in vivo does have an
effect on virulence. Second, the 710L3H mutation in E2 leads
to reduced virulence only in combination with the adaptive
mutations in Erns. The mechanism by which this mutation
affects virulence is not clear. As discussed before, the overall
(or local) positive charge of the virion seems to be correlated
with attenuation of CSFV strain Brescia in vivo. Thus, the
mutation in E2 might contribute to the positive charge of the
virion and reduced spread in vivo. Another mechanism by
which virulence might be affected is reduced spread of virus in
vivo in combination with changes in binding and/or penetration
of virus in host membranes leading to tissue tropism. Both Erns
and E2 are involved in the infection process of CSFV. Erns is
involved in HS-mediated entry, which is the first step in the
infection process, followed by a possible interaction of E2 with
other secondary receptors for adhesion and penetration. Both
processes could be disturbed by the adaptive amino acid mu-
tations in Erns and E2 leading to tissue tropism.
Detailed studies of processing and surface structure are
needed to obtain insight into how CSFV binds to and associ-
ates with host cells. In addition, more-detailed studies on the
interaction or replication of CSFV, either cell adapted or in
vivo generated, with specific target host cells might elucidate
more genetic determinants of virulence for CSFV.
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